CompletedPhase 2NCT05025332

An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001)

Studying Pitt-Hopkins syndrome

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Neuren Pharmaceuticals Limited
Principal Investigator: James Shaw
Neuren Pharmaceuticals
Intervention: NNZ-2591(drug)
Enrollment: 28 target
Eligibility: 3-17 years · All sexes
Timeline: 2022 – 2024

Study locations (5)

University of Alabama at Birmingham, Birmingham, Alabama, United States
University of California at San Francisco, San Francisco, California, United States
Children's Hospital Colorado, Aurora, Colorado, United States
Rush University Medical Center, Chicago, Illinois, United States
UT Southwestern, Dallas, Texas, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05025332 on ClinicalTrials.gov

Other trials for Pitt-Hopkins syndrome

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE1, PHASE2NCT07135050
Phase 1/2 Study of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome
Mahzi Therapeutics

See all trials for Pitt-Hopkins syndrome →

← Back to all trials